Biora Therapeutics, Inc.
BIORQ
$0.1174
-$0.0086-6.83%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.00K | 318.00K | 542.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.00K | 318.00K | 542.00K | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 32.00K | 318.00K | 542.00K | -- | -- |
| SG&A Expenses | 10.65M | 8.40M | 9.05M | 7.23M | 12.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.26M | 16.10M | 16.06M | 13.34M | 23.32M |
| Operating Income | -16.23M | -15.79M | -15.52M | -13.34M | -23.32M |
| Income Before Tax | -22.26M | 6.40M | -4.14M | -15.73M | -73.45M |
| Income Tax Expenses | -44.00K | -67.00K | 48.00K | -95.00K | 1.00K |
| Earnings from Continuing Operations | -22.22M | 6.47M | -4.19M | -15.63M | -73.45M |
| Earnings from Discontinued Operations | 3.82M | -- | -- | 219.00K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.40M | 6.47M | -4.19M | -15.41M | -73.45M |
| EBIT | -16.23M | -15.79M | -15.52M | -13.34M | -23.32M |
| EBITDA | -16.12M | -15.68M | -15.41M | -13.22M | -23.20M |
| EPS Basic | -5.04 | 1.81 | -1.43 | -6.21 | -48.89 |
| Normalized Basic EPS | -1.98 | 1.12 | -0.84 | -3.96 | -8.43 |
| EPS Diluted | -5.04 | -0.35 | -1.43 | -6.21 | -48.89 |
| Normalized Diluted EPS | -1.98 | 0.54 | -0.84 | -3.96 | -8.43 |
| Average Basic Shares Outstanding | 3.65M | 3.57M | 2.93M | 2.48M | 1.50M |
| Average Diluted Shares Outstanding | 3.65M | 7.42M | 2.93M | 2.48M | 1.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
